European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live06-05

European equities traded in the US as American depositary receipts were higher Wednesday morning, rising 0.93% to 1,436.34 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and pharmaceutical company Ascendis Pharma (ASND), which rose 3.1% and 2.8% respectively. They were followed by biotech firm BioNTech (BNTX) and 3D printer company Materialise (MTLS), which were up 1.8% and 1.6% respectively.

The decliners from continental Europe were led by biopharmaceutical company Genfit (GNFT) and hotel booking site trivago (TRVG), which lost 2.1% and 1.8% respectively. They were followed by internet browser company Opera (OPRA) and biopharmaceutical company Calliditas Therapeutics (CALT), which fell 1.6% and 1.4% respectively.

From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Amarin (AMRN), which climbed 8.1% and 5.2% respectively. They were followed by biopharmaceutical companies Mereo BioPharma Group (MREO) and Adaptimmune Therapeutics (ADAP), which were up 5.1% and 4% respectively.

The decliners from the UK and Ireland were led by utilities company National Grid (NGG) and financial services firm Lloyds Banking Group (LYG), which fell 2.3% and 2.1% respectively. They were followed by biopharmaceutical firm Biodexa Pharmaceuticals (BDRX) and pharmaceutical company Avadel Pharmaceuticals (AVDL), which were down 2% and 1.9% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment